Curasight updates Phase I uTREAT glioblastoma trial protocol to add cohort without blood-brain barrier disruption

• Curasight proposed a protocol update for its Phase I uTREAT trial in glioblastoma to broaden data for the next study phase.
• No trial results were reported; the updated design aims to test whether uTREAT can be delivered without blood-brain barrier disruption.
• New enrollees would form a separate cohort, enabling a direct comparison with earlier patients treated with barrier disruption.
• The amendment raises the minimum enrollment to ensure at least 6 patients receive uTREAT without barrier disruption, extending recruitment timelines.
• Implementation depends on regulatory and ethics clearance; the company expects to update investors as material developments occur.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curasight A/S published the original content used to generate this news brief via Cision (Ref. ID: 20260726:BIT:1878:0) on July 27, 2026, and is solely responsible for the information contained therein.